At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 72 enrolled
Drug / intervention
Abemaciclibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Randomized Phase 2 Study of the Impact of Food on Tolerability When Receiving Abemaciclib for Patients With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Abemaciclib for Metastatic Breast Cancer. Completed, enrolled 72 participants across 15 sites in 5 countries.
Detailed Summary
The main purpose of this study is to examine the side effects that participants with metastatic breast cancer experience when taking abemaciclib with or without food.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesAustralia, Belgium, Russia, Spain, Turkey (Türkiye)
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartNov 2018
Primary CompletionJul 2019
Study CompletionMar 2023
TodayJul 2026
First PostedOct 12, 2018
Enrollment StartNov 28, 2018
Primary CompletionJul 29, 2019
Study CompletionMar 9, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7.7 years ago
Interventions
Abemaciclibdrug
Administered orally.